Objective: Our objective was to explore whether 25(OH)D in pregnancy, umbilical cord blood (UCB), or in infancy was associated with infant growth.
.
In children, severe vitamin D deficiency increases the risk of rickets, which can lead to growth impairment (10) . Indeed, among low-birth-weight infants in India, among whom vitamin D deficiency was common, a weekly vitamin D supplementation of 35 mg improved infant linear growth compared with placebo (11) . However, a Canadian vitamin D intervention study (with vitamin D doses of 10, 20, 30 , and 40 mg) in 132 healthy infants showed no difference between the groups in growth at 11 months despite different 25(OH)D, although this study may have been underpowered (12) .
Previous studies have largely lacked subjects with high 25(OH)D concentrations and have focused on the effects of very low vitamin D status or vitamin D supplementation in vitamin D-deficient children on infant growth. In addition, studies have rarely included data for both maternal and infant 25(OH)D concentrations. In Finland, vitamin D supplementation is recommended for pregnant women and all children, and vitamin D food fortification is used in liquid dairy products and fat spreads (13) . Our objective was to explore whether 25(OH)D in pregnancy, umbilical cord blood (UCB), or infancy at 12 months of age are associated with growth parameters in 6-month-old and 12-month-old infants. This study was part of the Vitamin D Intervention in Infants (VIDI) study, a randomized trial on vitamin D supplementation with the standard (10 mg) or a higher dose (30 mg) of vitamin D 3 in infants.
Materials and Methods

Subjects
At Kätilöopisto Maternity Hospital (Helsinki, Finland), 987 families were recruited into the VIDI study between January 2013 and June 2014, during the mother's hospital stay after delivery. Written informed consent was obtained from the parents at recruitment. This study was conducted according to the guidelines laid down in the Declaration of Helsinki. Ethical approval was obtained from the Research Ethics Committee of the Hospital District of Helsinki and Uusimaa (107/13/03/03/ 2012). The project protocol is registered at clinicaltrials.gov (NCT01723852). According to the inclusion criteria, the mothers were of Northern European origin without regular medication and with singleton pregnancy. Exclusion criteria for the newborns were: nasal continuous positive airway pressure treatment or need for nasogastric tube .1 day, intravenous glucose infusion, seizures, and duration of phototherapy .3 days. The infants were born between 37 and 42 weeks of gestation with birth weights appropriate for gestational age [SD score (SDS) between 22.0 and 2.0].
Infants were randomized to receive daily vitamin D 3 supplementation with either 10 mg or 30 mg from age 2 weeks to 24 months. We have previously reported that at the age of 12 months, in addition to the supplemental dose, nonbreastfed infants (n = 476) received 0.6 to 28.3 and breastfed infants (n = 263) 0 to 30.7 mg of vitamin D daily from food (14) . The VIDI study included three study visits at the ages of 6, 12, and 24 months and multiple retrospectively and prospectively collected questionnaires. A detailed description of the recruitment and study protocol has been reported previously (15) .
Of the recruited 987 families, 12 did not meet the inclusion criteria and were excluded, leaving 975 study participants. In addition, 87 infants withdrew prior to 6 months, and a further 15 withdrew prior to 12 months, leaving 873 infants with body size measurements. Of these infants, 74 did not have 25(OH)D measurements, and 1 infant was excluded after a diagnosis of Rieger syndrome. The final study cohort for this study thus comprised 798 infants (Supplemental Figure 1) . Of the infants, 51% (409 out of 798) were girls. Number of subjects varies in different analyses due to partial missing data and is reported in the tables. As data on the infants' vitamin D supplemental dose were unavailable for this study, we adjusted the analyses for Infant 25(OH)D at 12 months as a marker of total vitamin D intake including supplements.
Biochemical analyses
25(OH)D measurements were obtained at three time points for each subject. Pregnancy serum samples were collected at prenatal clinics on average (SD) at gestational week 11 (2) (19) . Furthermore, we divided subjects into groups based on 25(OH) D concentrations using an additional cutoff values of 75 nmol/L, which has been considered a lower threshold value for bone health (18) , and 125 nmol/L, above which values have been related to health risks (19) .
Parental data
Parental data were obtained from a self-administered baseline questionnaire, filled out after delivery, and from medical records. Parental heights (centimeters) and weights (kilograms) before pregnancy and parity were collected primarily from the prenatal maternity card or from our baseline questionnaire. Parental heights were standardized into sex-specific z scores. Prepregnancy body mass index (BMI) was calculated (kilograms per meters squared). Duration of gestation was determined by firsttrimester ultrasound examination.
Parental education level was categorized into lower and higher education (lower is lower or upper secondary or postsecondary nontertiary education or less than a bachelor degree, and higher is first or second stage of tertiary education or at least a bachelor degree), according to the highest received degree of the parents. Parental smoking status was assessed before pregnancy and at infant age of 24 months and applied as a merged previous and current smoking status. Family income level was inquired with a questionnaire completed at infant age of 24 months.
Infant data
Birth size was measured by midwives according to standard procedure, and we collected data from birth records. Infant weight (kilograms), length (centimeters), and head circumference (centimeters) were measured at the 6-month and 12-month follow-up visits by a pediatrician or a research nurse. In addition, at the 12-month follow-up visit, midupper-arm circumference (MUAC; millimeters) was measured. Length was measured with a tabletop meter in a supine position and weight with an electronic scale (Seca GmbH, Hamburg, Germany). Weight, length, length-adjusted weight, and head circumference were expressed as SDS using age-specific and sex-specific Finnish references (20) . Weight, length, length-adjusted weight, and head circumference were considered normal when between 22.0 and 2.0 SDS. MUAC was standardized into sex-specific z score within the current study population, as no Finnish normative data exist. Duration of breastfeeding was determined based on repeated questionnaires in prospectively collected study diaries.
Statistical analysis
The normality of the variables was visually inspected. Infant and family characteristics were reported as means, SDs, and percentages. Nonparametric methods were used where appropriate. Independent variables were Pregnancy, UCB, and Infant 25(OH)D concentrations, and outcome variables were infant size at 6 and 12 months of age (9 outcomes altogether). Covariates were chosen based on their statistically significant association with several outcome measures. To assess the independent effect of Pregnancy and UCB 25(OH)D on growth, we adjusted the analyses for Infant 25(OH)D concentration at 12 months of age as a marker of the postnatal supplemental vitamin D intake. Missing values of covariates were multiple imputed (five imputations). In tables with infant and family characteristics (Tables 1 and 2) , all values are nonimputed.
A change in infant growth (length, weight, length-adjusted weight, and head circumference) between birth and 6 and 12 months of age was calculated by saving the residuals from linear regression models of body size SDS at each successive age vs the corresponding body size SDS at all earlier ages (21) . These residuals were referred to as "conditional growth." The corresponding birth size and size at 6 months of age were adjusted for in the analyses of conditional growth. Using conditional growth indicators as outcomes enabled us to explore whether 25(OH)D had an effect on the growth rate among different growth periods.
Univariate and multivariate linear regression analysis was used to explore associations between 25(OH)D and infant growth and conditional growth. We used three regression models. In the tables, we show an unadjusted model 1 and model 2, which is adjusted for variables that are essential to describe the association between 25(OH)D concentration and early growth independent of genetic determinants of growth. These variables included SDS of the corresponding birth size, maternal and paternal height z scores, and Infant 25(OH)D [except in analyses in which Infant 25(OH)D served as the independent variable]. In the text, we report model 3, which is further adjusted for potential confounders that can be expected to have a causal effect on the predictor and outcome: maternal and paternal prepregnancy BMI, parental smoking status, parental education level, family income level, and duration of breastfeeding. The analyses on conditional growth were conducted in a similar manner. Quadratic associations were explored with linear regression by adding the corresponding 25(OH)D squared in the growth models 1 and 2. In models of linear regression, residuals were plotted to assess their normal distribution and evaluate heteroscedasticity. 
Results
Infant and family characteristics are presented in Tables 1  and 2 . Almost all infants had normal body size (weight and length between 22.0 and 2.0 SDS) at 6 and 12 months of age. Of the infants, 79% were partially breastfed at 6 months and 40% at 12 months of age. (Tables 3 and 4) . At 6 months, mothers whose Pregnancy 25(OH)D was .125 nmol/L had the shortest (in length; mean difference 0.41 SDS; P = 0.048), lightest (in weight; mean difference 0.63 SDS; P = 0.016), and thinnest (in length-adjusted weight; mean difference 0.70 SDS; P = 0.013) infants compared with the reference group (Fig. 1) . We found a quadratic association between Pregnancy 25(OH)D and length at 12 months (Table 4) . We also observed an inverse association between Pregnancy 25(OH)D and MUAC (Table 4 ). The 12-month MUAC was smaller in the group with Pregnancy 25(OH)D at 75 to 125 nmol/L (mean difference 0.17 SDS; P = 0.049) compared with the reference group (Fig. 2) . At 12 months of age, infants of mothers with the highest Pregnancy 25(OH)D were the thinnest (mean difference 0.60 SDS; P = 0.021) compared with the reference group (Fig. 2) .
Infants with higher UCB 25(OH)D were shorter at 6 months (Table 3 ) and had a smaller head circumference at 6 and 12 months, although this attenuated to nonsignificance when adjusted (Tables 3 and 4) . Furthermore, infants with UCB 25(OH)D .125 nmol/L were the shortest at 6 months compared with the reference group (mean difference 0.39 SDS; P = 0.011) (Fig. 1) . As demonstrated by conditional lengths, infants with higher UCB 25(OH)D grew more slowly between birth and 6 months but more rapidly between 6 and 12 months (Supplemental Tables 2  and 3 ). Newborns with UCB 25(OH)D ,50 nmol/L were the thinnest at 6 months (mean difference 0.45 SDS; P = 0.034) compared with the reference group (Fig. 1) . A higher Infant 25(OH)D at 12 months was associated with smaller length, weight, length-adjusted weight, and head circumference at 12 months, although the associations with length and head circumference attenuated with adjustments (Table 4) . Furthermore, infants with 25(OH) D .125 nmol/L at 12 months had the smallest weight (mean difference 0.25 SDS; P = 0.022) and lengthadjusted weight (mean difference 0.25 SDS; P = 0.032) compared with the reference group (Fig. 2) .
For the regression analyses assessing the relationship between 25(OH)D concentrations and growth (Tables 3  and 4) , we further adjusted for the following potential confounding factors: maternal and paternal prepregnancy BMI, parental smoking status, parental education level, family income level, and duration of breastfeeding) (data not shown). Results remained similar except for the association between Pregnancy 25(OH)D and MUAC at 12 months of age, which disappeared.
Discussion
In this study, we demonstrate that high 25(OH)D in the mother and infant were associated with slower postnatal growth in a large prospective study of healthy full-term infants. This study is among the few to explore whether maternal and infant vitamin D statuses were associated with growth parameters in 6-and 12-month-old infants. The study was carried out in a population of northern latitude but where severe vitamin D deficiency is rare. Almost all mothers and infants were vitamin D sufficient [25(OH)D $50 nmol/L]. Our main finding was counterintuitive: high 25(OH)D in pregnancy, UCB, and infancy associated with delayed growth in infants.
The main findings showed that mothers with Pregnancy 25(OH)D .125 nmol/L had the shortest (in length), lightest (in weight), and thinnest (in lengthadjusted weight) infants at 6 months of age. Infants of these mothers also had the lowest length-adjusted weight at 12 months of age. Similarly, infants with higher UCB 25(OH)D were shorter at 6 months of age, but those with 25(OH)D ,50 nmol/L were the lightest. As for length, we observed a slow linear growth until the age of 6 months and an accelerated growth from 6 to 12 months of age in those with higher UCB 25(OH)D. Furthermore, infants with higher vitamin D status at 12 months had lower weight and length-adjusted weight at 12 months (25) . However, we found that higher Pregnancy and UCB 25(OH)D predicted slower infant growth until 6 months of age. In the Bangladeshi study with 134 infants, of which 26% were stunted during the follow-up, maternal supplementation of 875 mg/wk resulted in divergent mean UCB 25(OH)D between supplemented and placebo-treated mothers (103 vs 39 nmol/L) (9) . Opposed to our findings, this study found that maternal supplementation increased infant length at 1 and 2 months but no longer at 4 and 6 months and then again at 12 months of age (9) . In older infants (9 to 18 months), the relation of maternal vitamin D status with infant growth has similarly been conflicting (5, 6, 8, 9, 22, 23, 25) . In our study, the possibly disadvantageous effect of high Pregnancy and UCB 25(OH)D on several infant growth indicators remained to some extent until 12 months of age. Our finding is somewhat contrary to a Dutch multiethnic study, in which slow fetal growth but Together, these results may indicate an inverse U-shaped association between maternal 25(OH)D and infant growth, as has been proposed to exist between maternal vitamin D status and fetal growth (26, 27) . We previously reported in this cohort an inverse relationship between UCB 25(OH)D and newborn head circumference (17) . This finding was still apparent at 6 and 12 months but attenuated when adjusting for birth head circumference and parental height. In addition to Pregnancy and UCB 25(OH)D, also high Infant 25(OH)D was negatively associated with postnatal growth; the strongest associations appeared with weight and length-adjusted weight. These findings are in line with a Danish study that found 25(OH)D (mean 77 nmol/L) at 9 months to associate negatively with length and BMI (28) . However, two previous vitamin D supplementation trials in infants found no effect on growth between different dosages (12, 29) . By contrast, in Indian low-birth-weight infants, the vitamin D supplementation from the age of 1 week until 6 months increased infant length and weight at 6 months but no longer at 3 to 6 years (11). In that study, vitamin D deficiency was highly prevalent in the placebo group (73%) (11) . The inconsistent findings on vitamin D and infant postnatal growth may be due to ethnic, genetic, geographical, nutritional status, and lifestyle differences several growth parameters, although the limited number of subjects in both extreme ends of the 25(OH)D range constrained our analysis. The inverse U-shaped or J-shaped relationship between vitamin D status and health is supported by observations in adults (33) . In addition, our previous finding of a positive association between UCB 25(OH)D and inflammatory markers further support the possible adverse effect of high 25(OH)D on infant health (34) . The rather high Pregnancy and UCB 25(OH)D in our cohort can be explained by the fact that almost all mothers (95%) in our study were taking vitamin D supplements during pregnancy, with a mean daily intake of 16 mg (16). In addition, vitamin Dfortified foods are commonly used in Finland (13) . In addition to vitamin D, folic acid is also recommended for pregnant women in Finland, from the planning of pregnancy until gestational week 12; however, this recommendation was not valid at the time of this study. Iron supplementation is not routinely recommended. With regard to infants, based on the VIDI study protocol, infants received vitamin D supplements of 10 mg or 30 mg daily, leading to relatively high 25(OH)D. Because our study only included infants born term with normal birth weight, it remains unknown whether these results can be extrapolated to children born preterm or with low or high birth weight.
Infant growth is regulated by several factors, including those related to mineral homeostasis, circulating endocrine factors, and local regulators of the growth plate function. The nature of our study did not allow us to explore potential mechanisms for adverse growth outcomes caused by high 25(OH)D concentrations. High vitamin D status may affect calcium and phosphate homeostasis. However, we have previously shown that whereas Infant 25(OH)D correlated positively with ionized calcium concentration, no severe hypercalcemia developed (35) . Furthermore, our previous study showed that urine calcium excretion was similar in 3-month-old infants supplemented with 10, 30, or 40 mg vitamin D 3 and that 25(OH)D did not correlate with bone parameters (29) . In the current study, the mean PTH concentration was lower in the higher 25(OH)D category, suggesting that there may be mild changes that could impact growth plate function (36) via the PTH-PTHrelated peptide axis or the calcium-sensing receptor (37 2 D, which in turn may have a negative effect on growth due to increased osteoclastogenesis (38) . In genetically modified mice, high maternal 1,25(OH) 2 D levels adversely affected the total amount of calcium stored in fetal bones (39) . The GH-IGF-1 axis plays an important role in the regulation of childhood growth, and although some studies have shown a positive effect of vitamin D supplementation on IGF-1 in children (40) , it is unknown whether supranormal 25(OH)D concentrations have a similar positive effect.
A strength and limitation of this study is in the recruitment, which took place in a single hospital; this enabled standardized data collection, but a multicenter study might have resulted in a more diverse study population. A limitation was the inability to use data on infant vitamin D supplementation because of the ongoing double-blind intervention. However, we applied the attained 25(OH) D concentration as a reflection of the total vitamin D intake. Furthermore, the limited number of subjects with low 25(OH)D concentration may have restrained our analyses. We used multiple outcome variables, as we wanted to evaluate growth across the infantile period. The multiple outcome variables increase the possibility that some associations arise by chance. However, results are parallel with each other. The strength of our study is the varied and in-depth approach to analyze the relationships among Pregnancy, UCB, and Infant 25(OH)D on infant growth. In addition, we were able to adjust our analyses for several potential confounders to identify the independent role of vitamin D in growth regulation.
Conclusion
In our large cohort, high 25(OH)D concentrations in pregnancy, UCB, and infancy were associated with slower growth in infants at 6 and 12 months of age. Overall, our findings suggest an inverse U-shaped association between vitamin D status and infant postnatal growth. Although the underlying mechanisms and direct clinical implications remain to be further explored, our results indicate that, in Finland, an adequate maternal and infant vitamin D status has been achieved with a daily vitamin D supplementation of 10 mg and with vitamin D food fortification. We urge caution in aiming for a higher maternal or infant 25(OH)D concentration with excessive supplementation, as this might have unexpected and possibly disadvantageous effects on infant growth. 
